Top

Published in:

01-03-2015 | Laboratory Investigation

High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype

Authors: Yi Pu, Shouwei Li, Chuanbao Zhang, Zhaoshi Bao, Zhengxiang Yang, Lihua Sun

Published in: Journal of Neuro-Oncology | Issue 1/2015

Abstract

Chemokines are a superfamily of small heparin-binding cytokines that induce leukocytes to migrate to sites of inflammation or injury through interacting with specific transmembrane G protein-coupled receptors. Currently, attention is focused on chemokine/chemokine receptor pairs and their ability to promote tumor cell migration and angiogenesis. The chemokine receptor CXCR3 is involved in tumor metastasis and is used as a prognostic biomarker. However, its relationship with the clinicopathological features of primary glioblastoma multiforme (pGBM) and its potential prognostic value have yet to be investigated. Here, we report that high CXCR3 expression conferred poor survival in pGBM patients. Further analysis showed that CXCR3 served as an independent prognostic biomarker for pGBM patients. In addition, functional assays indicated that CXCR3 induced glioma cell invasion. Therefore, this evidence indicates CXCR3 is an independent prognostic factor for pGBM patients and promotes an invasive phenotype, which suggests a new potential biotarget for glioblastoma multiforme therapy.

Okumus NO, Gursel B, Meydan D, Ozdemir O, Odabas E, Gonullu G (2012) Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients. Ann Saudi Med 32(3):250–255. doi:10.5144/0256-4947.2012.250 PubMed

Drappatz J, Norden AD, Wen PY (2009) Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9(4):519–534. doi:10.1586/ern.09.10 CrossRefPubMed

Demuth T, Berens ME (2004) Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70(2):217–228. doi:10.1007/s11060-004-2751-6 CrossRefPubMed

Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64(4):458–478. doi:10.1007/s00018-007-6342-5 CrossRefPubMed

Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, Gonzalez-Herrero I, Sanchez-Garcia I, Silber JR, Horner PJ, Rostomily RC (2010) TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 9:194. doi:10.1186/1476-4598-9-194 CrossRefPubMedCentralPubMed

Thomas SL, Alam R, Lemke N, Schultz LR, Gutierrez JA, Rempel SA (2010) PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. Neuro Oncology 12(9):941–955. doi:10.1093/neuonc/noq048 CrossRefPubMedCentralPubMed

Fulton AM (2009) The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 11(2):125–131CrossRefPubMed

Asadi-Moghaddam K, Chiocca EA, Lawler SE (2010) Potential role of miRNAs and their inhibitors in glioma treatment. Expert Rev Anticancer Ther 10(11):1753–1762. doi:10.1586/era.10.168 CrossRefPubMed

Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, Kang C, You Y, Jiang T (2011) Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 1411:108–115. doi:10.1016/j.brainres.2011.07.002 PubMed

10.

Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M (2005) Chemokines in tumor progression and metastasis. Cancer Sci 96(6):317–322. doi:10.1111/j.1349-7006.2005.00059.x CrossRefPubMed

11.

Zlotnik A (2006) Chemokines and cancer. Int J Cancer 119(9):2026–2029. doi:10.1002/ijc.22024 CrossRefPubMed

12.

Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, Inaba K, Minato N, Oshima M, Taketo MM (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64(11):4010–4017. doi:10.1158/0008-5472.CAN-03-1757 CrossRefPubMed

13.

Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M, Taketo MM (2007) Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26(32):4679–4688. doi:10.1038/sj.onc.1210267 CrossRefPubMed

14.

Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8(3):490–498. doi:10.1158/1535-7163.MCT-08-0485 CrossRefPubMed

15.

Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66(15):7701–7707. doi:10.1158/0008-5472.CAN-06-0709 CrossRefPubMed

16.

Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125(11):2586–2594. doi:10.1002/ijc.24665 CrossRefPubMedCentralPubMed

17.

Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA, Martini V, Birnbaum D, Scoazec JY, Abello J, Al Saati T, Johnson MG, Sullivan TJ, Medina JC, Collins TL, Schmid-Alliana A, Schmid-Antomarchi H (2009) Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 100(11):1755–1764. doi:10.1038/sj.bjc.6605078 CrossRefPubMedCentralPubMed

18.

Wu Z, Han X, Yan J, Pan Y, Gong J, Di J, Cheng Z, Jin Z, Wang Z, Zheng Q, Wang Y (2012) The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma. Biomed Pharmacother 66(5):373–377. doi:10.1016/j.biopha.2011.12.003 CrossRefPubMed

19.

Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ (2008) The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 179(1):61–66. doi:10.1016/j.juro.2007.08.148 CrossRefPubMed

20.

Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, Romero IA (2008) Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol 199(1–2):35–45. doi:10.1016/j.jneuroim.2008.04.029 CrossRefPubMed

21.

Liu C, Luo D, Reynolds BA, Meher G, Katritzky AR, Lu B, Gerard CJ, Bhadha CP, Harrison JK (2011) Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 32(2):129–137. doi:10.1093/carcin/bgq224 CrossRefPubMedCentralPubMed

22.

Honeth G, Staflin K, Kalliomaki S, Lindvall M, Kjellman C (2006) Chemokine-directed migration of tumor-inhibitory neural progenitor cells towards an intracranially growing glioma. Exp Cell Res 312(8):1265–1276. doi:10.1016/j.yexcr.2005.12.018 CrossRefPubMed

23.

Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J, Wang X, You Y, Yang Z, Liu N (2011) MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res 1389:9–18. doi:10.1016/j.brainres.2011.03.013 CrossRefPubMed

24.

Zhang JP, Lu WG, Ye F, Chen HZ, Zhou CY, Xie X (2007) Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma. Int J Gynecol Cancer 17(2):478–483. doi:10.1111/j.1525-1438.2007.00786.x CrossRefPubMed

25.

Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I (2007) Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98(11):1652–1658. doi:10.1111/j.1349-7006.2007.00606.x CrossRefPubMed

26.

Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226–244. doi:10.1016/j.canlet.2008.04.050 CrossRefPubMed

27.

Robledo MM, Bartolome RA, Longo N, Rodriguez-Frade JM, Mellado M, Longo I, van Muijen GN, Sanchez-Mateos P, Teixido J (2001) Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 276(48):45098–45105. doi:10.1074/jbc.M106912200 CrossRefPubMed

28.

Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A (2007) CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 60(6):596–599. doi:10.1136/jcp.2005.032144 CrossRefPubMedCentralPubMed

29.

Wu Q, Dhir R, Wells A (2012) Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 11:3. doi:10.1186/1476-4598-11-3 CrossRefPubMedCentralPubMed

30.

Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM (2000) The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 95(2):627–632PubMed

31.

Flynn G, Maru S, Loughlin J, Romero IA, Male D (2003) Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol 136(1–2):84–93CrossRefPubMed

32.

Bajetto A, Barbieri F, Dorcaratto A, Barbero S, Daga A, Porcile C, Ravetti JL, Zona G, Spaziante R, Corte G, Schettini G, Florio T (2006) Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochem Int 49(5):423–432. doi:10.1016/j.neuint.2006.03.003 CrossRefPubMed

Title: High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype
Authors: Yi Pu
Shouwei Li
Chuanbao Zhang
Zhaoshi Bao
Zhengxiang Yang
Lihua Sun
Publication date: 01-03-2015
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1692-y

At a glance: The STEP trials

Springer Medicine

High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases

p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk

Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells

Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells

Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins